1. Home
  2. TMDX vs GDS Comparison

TMDX vs GDS Comparison

Compare TMDX & GDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMDX
  • GDS
  • Stock Information
  • Founded
  • TMDX 1998
  • GDS 2001
  • Country
  • TMDX United States
  • GDS China
  • Employees
  • TMDX N/A
  • GDS N/A
  • Industry
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • GDS Computer Software: Programming Data Processing
  • Sector
  • TMDX Health Care
  • GDS Technology
  • Exchange
  • TMDX Nasdaq
  • GDS Nasdaq
  • Market Cap
  • TMDX 4.7B
  • GDS 3.8B
  • IPO Year
  • TMDX 2019
  • GDS 2016
  • Fundamental
  • Price
  • TMDX $86.26
  • GDS $22.33
  • Analyst Decision
  • TMDX Buy
  • GDS Strong Buy
  • Analyst Count
  • TMDX 10
  • GDS 4
  • Target Price
  • TMDX $138.20
  • GDS $18.29
  • AVG Volume (30 Days)
  • TMDX 2.2M
  • GDS 1.2M
  • Earning Date
  • TMDX 10-28-2024
  • GDS 11-19-2024
  • Dividend Yield
  • TMDX N/A
  • GDS N/A
  • EPS Growth
  • TMDX N/A
  • GDS N/A
  • EPS
  • TMDX 0.94
  • GDS N/A
  • Revenue
  • TMDX $401,090,000.00
  • GDS $1,448,934,069.00
  • Revenue This Year
  • TMDX $83.25
  • GDS $18.06
  • Revenue Next Year
  • TMDX $26.27
  • GDS $17.32
  • P/E Ratio
  • TMDX $94.29
  • GDS N/A
  • Revenue Growth
  • TMDX 109.09
  • GDS 9.08
  • 52 Week Low
  • TMDX $63.86
  • GDS $5.01
  • 52 Week High
  • TMDX $177.37
  • GDS $24.74
  • Technical
  • Relative Strength Index (RSI)
  • TMDX 31.88
  • GDS 53.00
  • Support Level
  • TMDX $82.70
  • GDS $22.10
  • Resistance Level
  • TMDX $98.88
  • GDS $23.31
  • Average True Range (ATR)
  • TMDX 5.52
  • GDS 1.19
  • MACD
  • TMDX 1.30
  • GDS -0.06
  • Stochastic Oscillator
  • TMDX 15.58
  • GDS 45.10

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About GDS GDS Holdings Limited ADS

GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. It has aggressively raised capital over the past four years for expansion. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.

Share on Social Networks: